Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

TSXV:ARCH - Post Discussion

View:
Post by Viking2233 on Jul 14, 2023 9:06am

Shorts

Well not much happening here during middle of summer. We continue to eagerly wait for the 3rd party data review of phase 2 trial. I have noticed a difference in trading the past 5 days. The volume is much lower and both CIBC and Scotiabank have disappeared on the sell side. We seem to be holding the $2.08-$2.10 range.

I believe it is still premature to think the shorts have moved on but my fingers are crossed that this in fact is the case.

The third party data is long overdue, I wonder if management is holding back the data to release it with start of the next trial in the fall.

I still cannot understand how we did not get a major gap up to $7-10 range from the last 3 new releases, they were major catalysts.

1. $5M in government grants which eliminated any need for dilution to fund next trial in the fall.

2. Increased Dosage Trial produced positive results which will enhance future data from trials

3. FDA approval for phase 2 AKI trial to commence in the fall.

This stock is coiling to explode and may be your last chance to see the share price below $10 on it way to $50+
Comment by TechTitan on Jul 14, 2023 11:51pm
"Fingers crossed CIBC and Scotia shorts are gone"...Why post your tears here for them to read?  $10 a share!? Then $50+ a share!??? Haha Wow! Get real and look at that chart. This can barely hang on above $1.50 US / 2$ CAD right now. 
Comment by Viking2233 on Jul 16, 2023 9:56am
Tech Titan, there is a simple reason you have zero likes  since your inception, you have nothing of value to add. Why are you even viewing this board? Why would you comment on this board. It is healthy to have both bull and bear comments listed but simply posting to attack a person has no value to anyone. If you have valid comments regarding the company, its science or trials that ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities